cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.14278/rodare.2537
title: µCT data of two drill cores of fractured crystalline rock (Grimsel)

description: Two crystalline rock drill cores from the Grimsel site were scanned with a Nikon XT H 225 - scanner. The samples were prepared (formatted and cast in epoxy) by UJV Rez, Czech Republic. The CT-data were acquired and processed at HZDR-FWOT. Sample 1 (GAM_UJV_1C_1) contains a complex system of interconnected fractures.<br> Sample 2 (GAM_UJV_1C_2) contains one single end-to-end fracture with larger aperture. Size of both samples: Diameter 80 mm, length 165 mm. Two tomograms were acquired for both samples:<br> 1) Complete drill core as one scan, voxel size ca. 75 µm.<br> 2) HR-tomogram merged from three sections with maximum resolution, voxel size ca. 40 µm. The tomograms were stored as 3D-raw files. Data format, acquisition parameters, and processing workflow, are documented in the tomogram header files (nrrd-format (text): see https://teem.sourceforge.net/nrrd/format.html).<br> This data format is importable into open-source visualization programs as 3D slicer (https://www.slicer.org) or Paraview (https://www.paraview.org). The data processing has been conducted with Avizo (https://www.thermofisher.com/de/de/home/electron-microscopy/products/software-em-3d-vis/avizo-software.html). Files:<br> Sample 1<br> GAM_UJV_1C_1_complet-2_01_NLM: Graylevel image of complete sample, ring artifact removal, non-local-means filter<br> GAM_UJV_1C_1_complet-2_01_thresholded: Tentative label image of complete sample, threshold segmentation with manual edit<br> Merged-GAM_UJV_1C_1_HR.Frac_section: Graylevel image of merged fracture section, unfiltered<br> Merged-GAM_UJV_1C_1_HR.Frac_section.Threshold: Tentative label image of merged fracture section, adaptive threshold segmentation with manual edit<br> GAM_UJV_1C_1_complet_2.png: Figure of complete sample <br> GAM_UJV_1C_1_HR_Frac_Y2.png: Figure of merged high-resolution tomogram Sample 2<br> GAM_UJV_1C_2_complet_01.filtered: Graylevel image of complete sample, ring artifact removal, non-local-means filter<br> GAM_UJV_1C_2_complet_01.filtered.thresholded: Tentative label image of complete sample, threshold segmentation with manual edit<br> Merged-GAM_UJV_1C_2_A_01.Frac_section.filtered: Graylevel image of merged fracture section, ring artifact removal, non-local-means filter<br> Merged-GAM_UJV_1C_2_A_01.Frac_section.filtered.segm: Tentative label image of merged fracture section, threshold segmentation with manual edit<br> GAM_UJV_1C_2_complett_2.png: Figure of complete sample<br> GAM_UJV_1C_2_HR_Frac_Y2.png: Figure of merged high-resolution tomogram Original acquistion data are stored on the HZDR bulk data storage system and available for reprocessing on request. <br> Financial support was granted from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 847593 (EURAD, WP FUTURE, task 2.2).<br>
DOI: 10.5281/zenodo.10061194
title: Understanding the Performance-Energy Tradeoffs of Object-Relational Mapping Frameworks
DOI: 10.6084/m9.figshare.24321199
title: Evaluation of the non-linearity of NA808 in liver not reflected in plasma using a rat pharmacokinetic study and PBPK modelling

description: When NA808, a potent HCV replication inhibitor, was intravenously administered to rats, it was distributed to the liver. The AUC ratio in the liver of 20 mg/kg to 2 mg/kg was greater than the dose ratio, whereas exposure in plasma was increased in a dose-proportional manner. Saturation of biliary excretion was also shown at 20 mg/kg.NA808 was revealed to be a substrate for both OATP1B and MRP2 transporters by an <i>in vitro</i> study using OATP1B1-MRP2 expressing cells. [<sup>14</sup>C]NA808 was taken up into the cells by OATP1B1 and excreted from cells by MRP2 efficiently (P<sub>app</sub> ratio: 24.2–70.2). The P<sub>app</sub> ratio decreased with increasing NA808 concentration.PBPK modelling was constructed to display the blood and liver concentration time profile and biliary excretion of NA808. This model analysis was able to reproduce the pharmacokinetics in rats; the degree of increase in the liver exposure from 2 to 20 mg/kg was more than dose-proportional and was greater than the increase in the blood exposure due to saturation of efflux transporters.In drug development, to avoid unexpected toxicity in tissues, it is important to consider the potential for tissue non-linearity with linear plasma exposure based on pre-clinical data and PBPK modelling. When NA808, a potent HCV replication inhibitor, was intravenously administered to rats, it was distributed to the liver. The AUC ratio in the liver of 20 mg/kg to 2 mg/kg was greater than the dose ratio, whereas exposure in plasma was increased in a dose-proportional manner. Saturation of biliary excretion was also shown at 20 mg/kg. NA808 was revealed to be a substrate for both OATP1B and MRP2 transporters by an <i>in vitro</i> study using OATP1B1-MRP2 expressing cells. [<sup>14</sup>C]NA808 was taken up into the cells by OATP1B1 and excreted from cells by MRP2 efficiently (P<sub>app</sub> ratio: 24.2–70.2). The P<sub>app</sub> ratio decreased with increasing NA808 concentration. PBPK modelling was constructed to display the blood and liver concentration time profile and biliary excretion of NA808. This model analysis was able to reproduce the pharmacokinetics in rats; the degree of increase in the liver exposure from 2 to 20 mg/kg was more than dose-proportional and was greater than the increase in the blood exposure due to saturation of efflux transporters. In drug development, to avoid unexpected toxicity in tissues, it is important to consider the potential for tissue non-linearity with linear plasma exposure based on pre-clinical data and PBPK modelling.
DOI: 10.6084/m9.figshare.24321199.v1
title: Evaluation of the non-linearity of NA808 in liver not reflected in plasma using a rat pharmacokinetic study and PBPK modelling

description: When NA808, a potent HCV replication inhibitor, was intravenously administered to rats, it was distributed to the liver. The AUC ratio in the liver of 20 mg/kg to 2 mg/kg was greater than the dose ratio, whereas exposure in plasma was increased in a dose-proportional manner. Saturation of biliary excretion was also shown at 20 mg/kg.NA808 was revealed to be a substrate for both OATP1B and MRP2 transporters by an <i>in vitro</i> study using OATP1B1-MRP2 expressing cells. [<sup>14</sup>C]NA808 was taken up into the cells by OATP1B1 and excreted from cells by MRP2 efficiently (P<sub>app</sub> ratio: 24.2–70.2). The P<sub>app</sub> ratio decreased with increasing NA808 concentration.PBPK modelling was constructed to display the blood and liver concentration time profile and biliary excretion of NA808. This model analysis was able to reproduce the pharmacokinetics in rats; the degree of increase in the liver exposure from 2 to 20 mg/kg was more than dose-proportional and was greater than the increase in the blood exposure due to saturation of efflux transporters.In drug development, to avoid unexpected toxicity in tissues, it is important to consider the potential for tissue non-linearity with linear plasma exposure based on pre-clinical data and PBPK modelling. When NA808, a potent HCV replication inhibitor, was intravenously administered to rats, it was distributed to the liver. The AUC ratio in the liver of 20 mg/kg to 2 mg/kg was greater than the dose ratio, whereas exposure in plasma was increased in a dose-proportional manner. Saturation of biliary excretion was also shown at 20 mg/kg. NA808 was revealed to be a substrate for both OATP1B and MRP2 transporters by an <i>in vitro</i> study using OATP1B1-MRP2 expressing cells. [<sup>14</sup>C]NA808 was taken up into the cells by OATP1B1 and excreted from cells by MRP2 efficiently (P<sub>app</sub> ratio: 24.2–70.2). The P<sub>app</sub> ratio decreased with increasing NA808 concentration. PBPK modelling was constructed to display the blood and liver concentration time profile and biliary excretion of NA808. This model analysis was able to reproduce the pharmacokinetics in rats; the degree of increase in the liver exposure from 2 to 20 mg/kg was more than dose-proportional and was greater than the increase in the blood exposure due to saturation of efflux transporters. In drug development, to avoid unexpected toxicity in tissues, it is important to consider the potential for tissue non-linearity with linear plasma exposure based on pre-clinical data and PBPK modelling.
DOI: 10.25345/c5s46hh3p
title: MassIVE MSV000093285 - Flavour analysis of Jasmine green tea
title: Metabolic analysis of Jasmine green tea during process.
DOI: 10.5281/zenodo.10068523
title: Effects of Layer Housing Systems on Egg Production and Quality, Hematological and Serum Metabolites of White Leghorn Layers.
DOI: 10.5281/zenodo.10068522
title: Effects of Layer Housing Systems on Egg Production and Quality, Hematological and Serum Metabolites of White Leghorn Layers.
DOI: 10.6084/m9.figshare.23805990.v2
title: <b>Unexpected complexity of sex chromosome evolution in haploid plants</b>

description: <b>Unexpected complexity of sex chromosome evolution in haploid plants</b>
DOI: 10.57841/casdc.0002956
title: 导叶和可调扩压器调节时对离心压缩机性能变化规律的研究
DOI: 10.57841/casdc.0002957
title: 压缩空气储能系统中带进气室和扩压器的轴流涡轮流动特性研究
DOI: 10.57841/casdc.0002958
title: NACA叶型对CAES低展弦比向心涡轮效率提升研究
DOI: 10.57841/casdc.0002959
title: 单级和多级压缩空气储能系统的有限时间热力学特性研究
DOI: 10.57841/casdc.0002960
title: 轴流涡轮转子与扩压器匹配参数对流动损特性影响的研究
DOI: 10.6084/m9.figshare.24304452.v1
title: Sprint and jump performances of female athletes are enhanced in the evening but not associated with individual chronotype

description: Sprint and jump performances represent performance-determining parameters in individual and team sports. Fluctuations in performance depending on the daytime raise the question of the best time to train and compete. Given the scarce research on females, this study aimed to analyze the influence of daytime on sprint and jump performances and to investigate whether the performance difference is related to the chronotype. Thus, 23 female sports students completed a questionnaire to assess their chronotype followed by performing two 30 m sprints, 5 Repeated Jump Tests (5RJT), and countermovement jumps (CMJ) in the morning (7:00–9:00 h) and evening (17:00–19:00 h). Time after 5 m, 10 m, and 30 m during the sprints, reactive strength index (RSI) during the 5RJTs, and jump height during the CMJs were examined. The performance during the 30 m sprint (t(22) = 5.28, <i>p</i> &lt; 0.01 moderate effect size: 0.50) and the two jump tests (5RJT: t(22) = 8.27, <i>p</i> &lt; 0.01 large effect size: 0.95; CMJ: t(22) = 5.46, <i>p</i> &lt; 0.01 moderate effect size: 0.79) were significantly better in the evening than in the morning. There was no significant correlation between chronotype and the time-of-day effect. The results should be considered when planning training and competition.
DOI: 10.6084/m9.figshare.24304452
title: Sprint and jump performances of female athletes are enhanced in the evening but not associated with individual chronotype

description: Sprint and jump performances represent performance-determining parameters in individual and team sports. Fluctuations in performance depending on the daytime raise the question of the best time to train and compete. Given the scarce research on females, this study aimed to analyze the influence of daytime on sprint and jump performances and to investigate whether the performance difference is related to the chronotype. Thus, 23 female sports students completed a questionnaire to assess their chronotype followed by performing two 30 m sprints, 5 Repeated Jump Tests (5RJT), and countermovement jumps (CMJ) in the morning (7:00–9:00 h) and evening (17:00–19:00 h). Time after 5 m, 10 m, and 30 m during the sprints, reactive strength index (RSI) during the 5RJTs, and jump height during the CMJs were examined. The performance during the 30 m sprint (t(22) = 5.28, <i>p</i> &lt; 0.01 moderate effect size: 0.50) and the two jump tests (5RJT: t(22) = 8.27, <i>p</i> &lt; 0.01 large effect size: 0.95; CMJ: t(22) = 5.46, <i>p</i> &lt; 0.01 moderate effect size: 0.79) were significantly better in the evening than in the morning. There was no significant correlation between chronotype and the time-of-day effect. The results should be considered when planning training and competition.
DOI: 10.6084/m9.figshare.24356015
title: The effect of non-pharmacological interventions on sleep quality in people with sleep disturbances: A systematic review and a meta-analysis

description: Sleep is the elixir of life. Both healthy populations and patients with chronic diseases experience sleep disturbances in their lifetime. Pharmacological agents to induce sleep in individuals with sleep disturbances pose side effects like tolerance and dependence, warranting the development of alternative non-pharmacological interventions with less or no adverse effects. However, deciphering comprehensive evidence on the translational potential of these alternative therapies remains difficult. In the current paper, we systematically reviewed the recent literature on the effect of non-pharmacological interventions (NPIs) on improving sleep quality in both healthy and diseased populations experiencing sleep disturbances. We searched PubMed, Science Direct, Cochrane Controlled Trials, and Web of Science databases from inception to June 2022 for randomized controlled trials and cohort studies evaluating the sleep quality of individuals. We performed a meta-analysis using the random effects model with Pittsburgh Sleep Quality Index (PSQI) as an outcome measure to evaluate the effect of five distinct NPIs on sleep quality in normal and people with different medical conditions. Subgroup analyses and sensitivity analyses were done for heterogeneity analysis and to check the consistency of results, respectively. In 16 trials reporting on 1885 subjects, that all NPIs like Resistance Training (SMD −0.29, 95% CI −0.64 to 0.05; <i>p</i> = 0.09); Yoga (SMD −0.48, 95% CI −0.72 to −0.25; <i>p</i> &lt; 0.0001); Cognitive Behavioral Therapy (SMD −1.69, 95% CI −2.70 to −0.68; <i>p</i> = 0.001); Music (SMD −1.42, 95% CI −1.99 to −0.85; <i>p</i> &lt; 0.00001); Light (SMD −0.43, 95% CI −0.77 to −0.09; <i>p</i> = 0.01) have substantially decreased the global PSQI scores. The findings of the randomized studies and a cohort study included in qualitative synthesis demonstrated that the global PSQI scores improved significantly as compared to the placebo groups. Despite the limitations of clinical heterogeneity in subjects, our results demonstrate a positive impact of the studied NPIs on sleep quality in individuals experiencing sleep disturbances. However, comprehensive double-blinded controlled trials are indispensable in the future, emphasizing the objective sleep quality and inter-individual differences in response to the intervention.
DOI: 10.6084/m9.figshare.24356015.v1
title: The effect of non-pharmacological interventions on sleep quality in people with sleep disturbances: A systematic review and a meta-analysis

description: Sleep is the elixir of life. Both healthy populations and patients with chronic diseases experience sleep disturbances in their lifetime. Pharmacological agents to induce sleep in individuals with sleep disturbances pose side effects like tolerance and dependence, warranting the development of alternative non-pharmacological interventions with less or no adverse effects. However, deciphering comprehensive evidence on the translational potential of these alternative therapies remains difficult. In the current paper, we systematically reviewed the recent literature on the effect of non-pharmacological interventions (NPIs) on improving sleep quality in both healthy and diseased populations experiencing sleep disturbances. We searched PubMed, Science Direct, Cochrane Controlled Trials, and Web of Science databases from inception to June 2022 for randomized controlled trials and cohort studies evaluating the sleep quality of individuals. We performed a meta-analysis using the random effects model with Pittsburgh Sleep Quality Index (PSQI) as an outcome measure to evaluate the effect of five distinct NPIs on sleep quality in normal and people with different medical conditions. Subgroup analyses and sensitivity analyses were done for heterogeneity analysis and to check the consistency of results, respectively. In 16 trials reporting on 1885 subjects, that all NPIs like Resistance Training (SMD −0.29, 95% CI −0.64 to 0.05; <i>p</i> = 0.09); Yoga (SMD −0.48, 95% CI −0.72 to −0.25; <i>p</i> &lt; 0.0001); Cognitive Behavioral Therapy (SMD −1.69, 95% CI −2.70 to −0.68; <i>p</i> = 0.001); Music (SMD −1.42, 95% CI −1.99 to −0.85; <i>p</i> &lt; 0.00001); Light (SMD −0.43, 95% CI −0.77 to −0.09; <i>p</i> = 0.01) have substantially decreased the global PSQI scores. The findings of the randomized studies and a cohort study included in qualitative synthesis demonstrated that the global PSQI scores improved significantly as compared to the placebo groups. Despite the limitations of clinical heterogeneity in subjects, our results demonstrate a positive impact of the studied NPIs on sleep quality in individuals experiencing sleep disturbances. However, comprehensive double-blinded controlled trials are indispensable in the future, emphasizing the objective sleep quality and inter-individual differences in response to the intervention.
DOI: 10.6084/m9.figshare.24494893
title: Supplementary Dataset

description: Supplementary dataset pertaining to the co-evolutionary analysis as described in "A farnesyl-dependent structural role for CENP-E in expansion of the fibrous corona". This dataset contains fasta files of orthologous sequences, their alignments and HMM profiles of CENP-E, ROD, SPINDLY, ZW10 and ZWILCH as identified in this study.
DOI: 10.57841/casdc.0002961
title: 压缩空气储能的闭式径向流入式涡轮机损失分析研究
DOI: 10.34740/kaggle/dsv/6871472
title: AutoXGB
DOI: 10.34740/kaggle/dsv/6871473
title: OnlineFree
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n.1
title: 2-bromo-6-methyl-pyridine
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: This is a physical chemical entity[CHEBI_24431] associated with a molecule[CHEBI_25367]. The molecule[CHEBI_25367] can be described by the following structural desciptors[cheminf_000085]: InChI descriptor[cheminf_000113]: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3, and canonical SMILES descriptor[cheminf_000007]: Cc1cccc(n1)Br, and by the IUPAC name[cheminf_000107]: 2-bromo-6-methylpyridine. The physical chemical entity[CHEBI_24431] has a component solvent[CHEBI_46787] which is described by the canonical SMILES descriptor[cheminf_000007]: The physical chemical entity[CHEBI_24431] has the following Sample ID as registered in the research data repository chemotion (www.chemotion-repository.net, https://doi.org/10.25504/FAIRsharing.iagXcR): CRS-36489 The physical chemical entity[CHEBI_24431] can be described by the physical descriptors [CHEMINF_000025]: Melting point descriptor[CHEMINF_000256]: Boiling point descriptor[CHEMINF_000257]: Refractive index descriptor[CHEMINF_000253]: The physical chemical entity[CHEBI_24431] can be further described by the following assays[OBI:0000070][CHMO:0001133]: CHMO:0000601 | heteronuclear multiple bond coherence (HMBC) CHMO:0000599 | correlation spectroscopy (COSY) CHMO:0000596 | distortionless enhancement with polarization transfer (DEPT) CHMO:0000596 | distortionless enhancement with polarization transfer (DEPT) CHMO:0000604 | heteronuclear single quantum coherence (HSQC) CHMO:0000593 | 1H nuclear magnetic resonance spectroscopy (1H NMR) CHMO:0000595 | 13C nuclear magnetic resonance spectroscopy (13C NMR) The physical chemical entity[CHEBI_24431] was deposited to the Molecule Archive of the Karlsruhe Insitute of Technology (KIT) with the following Sample ID: Used ontologies: CHEBI - Chemical Entities of Biological Interest CHEMINF - chemical information ontology (information entities about chemical entities) CHMO - Chemical Methods Ontology OBI - Ontology for Biomedical Investigations
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n/chmo0000599
title: correlation spectroscopy (COSY) (2-bromo-6-methylpyridine)
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: dataset for correlation spectroscopy (COSY)
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n/chmo0000593
title: 1H nuclear magnetic resonance spectroscopy (1H NMR) (2-bromo-6-methylpyridine)
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: dataset for 1H nuclear magnetic resonance spectroscopy (1H NMR) 1H NMR (400 MHz, Chloroform-d [7.26 ppm], ppm) δ = 7.40 (t, J = 7.7 Hz, 1H), 7.27–7.25 (m, 1H), 7.08 (d, J = 7.6 Hz, 1H), 2.51 (s, 3H).
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n/chmo0000595
title: 13C nuclear magnetic resonance spectroscopy (13C NMR) (2-bromo-6-methylpyridine)
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: dataset for 13C nuclear magnetic resonance spectroscopy (13C NMR) 13C NMR (100 MHz, Chloroform-d [77.2 ppm], ppm) δ = 160.1 (Cq), 141.4 (Cq), 138.7 (CH), 125.1 (CH), 122.2 (CH), 24.3 (CH3).
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n/chmo0000601
title: heteronuclear multiple bond coherence (HMBC) (2-bromo-6-methylpyridine)
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: dataset for heteronuclear multiple bond coherence (HMBC)
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n/chmo0000596.1
title: distortionless enhancement with polarization transfer (DEPT) (2-bromo-6-methylpyridine)
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: dataset for distortionless enhancement with polarization transfer (DEPT)
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n/chmo0000604
title: heteronuclear single quantum coherence (HSQC) (2-bromo-6-methylpyridine)
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: dataset for heteronuclear single quantum coherence (HSQC)
DOI: 10.14272/sohdpiclicfsop-uhfffaoysa-n/chmo0000596
title: distortionless enhancement with polarization transfer (DEPT) (2-bromo-6-methylpyridine)
title: InChI=1S/C6H6BrN/c1-5-3-2-4-6(7)8-5/h2-4H,1H3

description: dataset for distortionless enhancement with polarization transfer (DEPT)
DOI: 10.6084/m9.figshare.23805990
title: <b>Complex sex chromosome evolution in a haploid plant lineage</b>

description: <b>Complex sex chromosome evolution in a haploid plant lineage</b>Please do not hesitate to contact the email addresses fuyuan@ibcas.ac.cn or abysw@abysw.com if you have any questions.Please cite our new paper when you use this data.
DOI: 10.6084/m9.figshare.23805990.v3
title: <b>Unexpected complexity of sex chromosome evolution in haploid plants</b>

description: <b>Unexpected complexity of sex chromosome evolution in haploid plants</b>